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Nontuberculous mycobacteria (NTM) are emergent pathogens whose importance in human health has been growing. After being
regarded mainly as etiological agents of opportunist infections in HIV patients, they have also been recognized as etiological
agents of several infections on immune-competent individuals and healthcare-associated infections. The environmental nature
of NTM and their ability to assemble biofilms on different surfaces play a key role in their pathogenesis. Here, we review the clinical
manifestations attributed to NTM giving particular importance to the role played by biofilm assembly.
1. Introduction
The genusMycobacterium includes remarkable human path-
ogens such as Mycobacterium tuberculosis and Mycobac-
terium leprae, both members of the M. tuberculosis complex
(MTC), and a large group of nontuberculous mycobacteria
(NTM). The NTM group comprises more than 172 different
species with distinct virulence features (http://www.bacterio
.net/mycobacterium.html). NTM usually exhibit saprophy-
tic, commensally, and symbiotic behaviors [1]. Although
mostly nonpathogenic, NTM are important environmental
opportunistic pathogens of humans and animals, including
poultry and fish [2, 3]. The NTM are ubiquitous in nature
sharing with humans and other animals a wide variety of
habitats. Over the past decades, NTM have been isolated
from natural resources such as water, soils, domestic and
wild animals, milk and food products and from artificial or
built resources, such as home water distribution systems like
showerhead sprays and sewers [2, 3].
Thenotification ofNTM infection cases is notmandatory,
in opposition to tuberculosis (M. tuberculosis infection).This
fact hampers the accurate knowledge of the impact of NTM
infections on public health. Nevertheless, it is largely accepted
that in western developed countries the prevalence of these
infections is growing as tuberculosis follows the opposite
trend [4].The impact ofNTM infections has been particularly
severe in immune-compromised individuals being associated
with opportunistic life-threatening infections in AIDS and
transplanted patients [5, 6]. Nevertheless, an increased inci-
dence of pulmonary diseases [7, 8] and healthcare-associated
infections (HAI) in immune-competent population high-
lighted the importance of NTM on human health [9, 10].
Medical devices related infections, one group of HAI, usually
linked with bacterial biofilm proliferation on these materials,
have been described for NTM [11]. The ubiquitous nature
of NTM even allows their persistence within biofilms on
other healthcare unit surfaces, such as water pipes. Biofilm
persistence within healthcare units represents a threat to
human health since it favors the onset and spread of HAI [12].
Biofilms are described as colonies of microorganisms
attached to each other and to a surface, in an irreversible
mode [13]. During biofilm development, bacteria suffer
several changes in their phenotypic state forming a het-
erogeneous, dynamic, and differentiated community. They
are part of a successful bacterial survival strategy in severe
environments, since biofilm provides protection against envi-
ronmental stressors, for example, antimicrobial agents and
disinfectants [14–16]. For this reason, NTMs biofilms are an
important research topic in mycobacteria pathogenesis [17].
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2. Epidemiology and Clinical Manifestations of
NTM Infections
Although being worldwide distributed, NTM experience
significant geographic differences in terms of species inci-
dence largely explained by the environmental nature of
these microorganisms. Bacteria from the Mycobacterium
avium complex (MAC) predominated in most western and
European Union (EU) countries, followed by M. gordonae
andM. xenopi [4]. In EU countries, anothermember ofMAC
(M. intracellulare) and the rapid growerM. fortuitum are the
next most frequent NTM isolated [18]. In the United States of
America, MACmembers are most often isolated, followed by
M. kansasii andM. abscessus [5].
A study conducted in Saudi Arabia (Middle East) ren-
dered an opposite picture to that described above. The major
species isolated were M. abscessus, M. fortuitum, and M.
intracellulare followed by M. kansasii, M. gordonae, and M.
avium [19]. The same is also observed in India where M.
fortuitum is the most frequently isolated NTM [20]. In other
eastern Asiatic countries located between Singapore (west)
and Japan (east), bacteria from MAC account for majority
of infections [20]. This peculiar aspect of NTM represents a
challenge in terms of infectious disease management. In dif-
ferent geographic spots, the etiological agent responsible for
the infection will be different requiring completely different
therapeutic approaches.
The accurate diagnosis requires the identification of the
etiological agent at the species level. The lack of a universal
identification algorithm together with the ability of NTM to
affect different organs exhibiting an age dependent tropism
makes this a difficult achievement. In adults, chronic lung
disease, bone infections, joints, and tendons are the most
frequent pathologies. In children, skin and lymphatic nodes
are the most affected organs. The majority of NTMs are
nonpathogenic to humans being frequently opportunistic
infectious agents. Rapid grower mycobacteria (RGM) and
slow grower mycobacteria (SGM) exhibit a differential epi-
demiology of infection. Usually, RGM infections are mostly
cutaneous and osteoarticular, whereas SGM infections are
located on lungs and lymph nodes [6].
Among the pathologies caused by NTM disseminated
infections were the first to attain the medical commu-
nity attention. Initially, disseminated NTM infections were
reported, almost exclusively, in severely immune-compro-
mised individuals, where disease progression can be very
rapid and even fatal. MAC members were the first to be
identified as etiologic agents of opportunistic infections
among AIDS patients back in the 1980s [21]. Until today,
MAC accounts for the overwhelming majority of cases with
M. avium being responsible for 90% of the cases [8, 21–24].
Excluding MAC, M. kansasii is the most common etiologic
agent of these infections. However, other NTM, such as M.
scrofulaceum, M. gordonae, M. haemophilum, M. genavense,
M. celatum, M. conspicuum, M. xenopi, M. fortuitum, M.
marinum, M. malmoense, and M. simiae, have also been
described as causing the pulmonary or disseminated disease
in AIDS patients [23, 25–34]. There are also reports of mixed
infections or infections caused by more than one NTM [35].
Disseminated NTM infections have also been described
in other immune-compromised populations, such as patients
with cystic fibrosis, chronic obstructive pulmonary disease,
renal failure, transplant recipients with chronic corticosteroid
use and TNF-𝛼, and leukemia [3, 18]. The frequency of these
infections remains on the rise, in immune-compromised
patients, due to the administration of immunosuppressive
drugs or genetic causes [6].
Many RGM are often involved in postsurgical or post-
traumatic infections, the most common being M. fortuitum,
M. chelonae, and M. abscessus [5, 6]. HAI of skin and soft
tissues due to these three species are caused by prolonged
use of intravenous or peritoneal catheters, liposuction, post-
mammoplasty surgical wounds, cardiac bypass, and postlaser
surgery cornea infections [36–41]. However, cases involving
new species, such as M. goodii and M. massiliense, have
recently been reported [42–45].
The respiratory infections, namely, affecting the lungs, are
the most frequent. Patients with structural lung diseases such
as chronic obstructive pulmonary disease, bronchiectasis,
cystic fibrosis (CF), pneumoconiosis, prior tuberculosis, pul-
monary alveolar proteinosis, and esophageal motility disor-
ders aremore prone to NTM infections [5]. Children with CF
are usually affected byM.abscessus and closely related species,
and adults are more frequently affected by members of the
MAC [6]. Although SGM are largely responsible for lung and
lymph node diseases, RGM, particularly M. immunogenum,
are most frequently involved in hypersensitivity pneumonia
[46, 47]. M. bolletii (now reclassified as M. abscessus subsp.
bolletii) is an emerging pathogen responsible for respiratory
tract infections in patients exhibiting compromised respira-
tory function, being very resistant to clarithromycin [48, 49].
Localized cervical lymphadenopathy is more common in
children aged between one and five years old [50–52] being
rarely observed in adults in the absence of HIV infection [5].
In recent decades, a major shift in the etiology of cervical
lymphadenitis was observed. M. scrofulaceum, previously
regarded as the predominant cause of the disease, has become
quite rare, with 80% of cases being attributed to MAC [52].
In Scandinavia, United Kingdom, Northern Europe, and
Israel, the incidence of this disease is increasing due to M.
malmoense and M. haemophilum [53–56]. The number of
new NTM species isolated from lymph node biopsies has
been reported to be increased, namely,M. lentiflavum andM.
bohemicum [57, 58].
While virtually all NTM species have been described as
etiologic agents of skin diseases, the species most frequently
causing localized infections of the skin and subcutaneous
tissue are M. fortuitum, M. abscessus, M. chelonae, M. mar-
inum, and M. ulcerans [5, 6]. A common feature in these
infections is exposure to contaminated water or infected fish.
Although most skin lesions caused by infected fish are due
to M. marinum, cases of infection by M. fortuitum and M.
chelonae have been described [6].M. ulcerans is the causative
agent of Buruli ulcer, the most common mycobacterial
disease following tuberculosis and leprosy [59, 60]. Cases
of mixed infections by NTM have been reported, as well
as outbreaks which are associated with invasive procedures
such as intramuscular injections and mesotherapy [61–68].
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Outbreaks in postoperative surgical settings, such as cosmetic
therapies, have also been described [43–45, 69].
3. Clinical Manifestations Associated with
NTMs Biofilms: A Particular Case
The association between NTM biofilms and human disease is
still recent, being unequivocally proven only for few species
[3]. As for many other aspects, the link between biofilm and
infection was first established forM. avium.This bacterium is
able to proliferate within showerheads as biofilm from which
infectious droplets could be released during a hot shower
[70]. A similar process has been described for the waterborne
pathogen Legionella pneumophila showing that this is not
a mycobacteria exclusive persistence/infectious strategy. The
isolation of NTM from biofilms collected in other water
systems, namely, present in healthcare units, supports this
route of dissemination of HAI by NTM [70, 71].
Another group of HAI with growing relevance is the
medical device associated infections. The microscopic exam-
ination of a prosthetic aortic valve removed from a patient
allowed the identification of a structure composed of NTM,
a thin fibrin matrix layer associated with CD38 macrophages
and a low number of platelets consistent with a biofilm. In
this case, the prosthetic valve endocarditis had as etiologic
agent the RGM M. fortuitum [72]. Another bacterium of
this group M. abscessus subsp. massiliense was linked to a
postchirurgical aesthetic breast implant case.The patient had
a simultaneous infection of the right gluteal region being an
example of surgical site contamination by NTM, and possible
contamination of chirurgical material [73]. The ability of
NTMs to form biofilms also contributes to the pathogenesis
of catheter-related bloodstream infections [12]. A study of CF
patients with lung infection demonstrated that M. abscessus
grows in microcolonies similar to a biofilm. The observed
phenotype is attributable to the cord growth formation of this
NTM [74].
Although few in number, the etiology of this clinical
manifestations is of great concern for public health. The
ability of NTM to persist within biofilm on medical devices,
both inside and outside the human body, together with the
increase use of invasive diagnostic and treatment procedures,
envisages an increase of these reports in the newer future.
4. NTM Transmission and Environment
In general, the opportunistic mycobacteria may become
pathogenic only in certain specific conditions. As so, since
they are environmental species, it is common to find them
colonizing the respiratory, gastrointestinal tract and skin, not
being a source of infection [71].The presence of opportunistic
pathogenic species (e.g.,M. avium) in a clinical sample is not
sufficient to attribute the classification of causal agent of the
disease. In these cases, it is mandatory to identify the same
NTMspecies both in the infection source and the patient [75].
The transmission of NTMs can be established through
environmental source or clinical settings to the patient, rather
than between patients [75, 76]. Humans could be infected by
NTM present in aerosol droplets by inhalation, ingestion, or
trauma events [3, 77]. The environmental sources of NTM
most relevant are water, soil, and dust. A characteristic of
mycobacteria, high hydrophobicity, is of key importance for
the success of infection. Hydrophobicity favors aerosoliza-
tion and consequently mycobacteria transmission and onset
of infection, for example, in alveoli. On the other hand,
hydrophobicity favors bacterial adhesion to surfaces promot-
ing biofilm assembly which could work as a disinfectant
and antibiotic resistance mechanism [3]. This aspect will be
detailed in another section of the paper.
In general, contamination of medical equipment by M.
tuberculosis has its origin in patients. However, in the case
of NTM, the source of contamination resides mainly in
tap water and can occur, among other possibilities, through
solutions used in the disinfection of endoscopes and during
automatic washing. In the last case, contamination can result
from the presence of a biofilm inside the instrument [78].
Since these devices are difficult to sterilize, theymay contami-
nate the sample during collection leading to pseudoinfections
[79].
5. Characteristics of Biofilm-Grown Bacteria
Biofilm assembly is a dynamic and complex process divided
in several phases, including reversible attachment, irre-
versible attachment, maturation, and dispersion [16]. The
attachment phase is dependent on electrostatic interactions
between bacteria and the surface. Bacteria only attach to a
surface if they sense stable nutrient concentrations, beneficial
temperature, and oxygen level [16]. During biofilm assembly,
bacteria secrete a matrix containing polymeric substances
such as polysaccharides, lipids, and nucleic acids. The extra-
cellular matrix plays a key role in biofilm architecture allow-
ing the assembly of a complex three-dimensional structure
[16, 80]. Bacteria within a mature biofilm are completely
differentiated, achieving their maximum replication rate
[81]. When the nutrient levels decrease, or bacteria density
increases in a certain area, bacteria can rapidly disperse and
colonize new spaces, in search for better conditions [16].
Quorum-sensing (QS) also known as bacteria cell-to-cell
communication mediated by autoinducer molecules plays a
regulatory role in this process being of particular importance
on both attachment and dispersion phases [82, 83].
In the case of NTM pathogenesis biofilm assembled
within healthcare units plays an important role, being more
common on water distribution systems and plumbing pipes
[84–87]. Evidence mounts in support of the observation
that tap water functions as a privilege channel for human
colonization and/or infection by NTM [66, 79, 88–90]. M.
avium is one of the most studied NTM regarding biofilm
production. ThisMycobacterium is able to assemble biofilms
even when incubated only with water explaining its presence
on showerheads, water distribution systems, and clinical
settings [91, 92]. Biofilm assembly was even exacerbated in
the presence of divalent cations and carbon sources [91].
As mentioned before, bacteria within biofilms exhibit
an enhanced resistance to antimicrobial agents, which could
be 10- to 1000-folds higher when compared to planktonic
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bacteria [93]. This phenomenon accounts, at least in part,
for an increase in bacterial virulence, being of particular
concern for bacteria naturally resistant to antimicrobials such
as NTM. Resistance to disinfectants, such as chlorine, has
been reported as being one of the factors responsible for
the colonization, persistence, and replication of NTM within
drinking water distribution systems [3, 75, 94]. Biofilm orga-
nization hampersNTMeradicationwith commondecontam-
ination practices and is relatively resistant to standard disin-
fectants [91], such as chlorine, organomercurials, and alkaline
glutaraldehydes [73, 95].Themechanisms responsible for this
phenomenon are less understood, but it is known that biofilm
growth depends on bacteria-surface affinity and environmen-
tal conditions.Mycobacterium fortuitum has a higher biofilm
development affinity in stainless steel, polyvinyl chloride, and
polycarbonate rather than copper and glass [91].
In the case of antibiotic resistance, several mechanisms
have been implicated in this virulence increase for bacteria
in general. One of them is horizontal gene exchanges favored
by the maximum proximity experienced by bacteria within
biofilms [96]. This gene transmission is a major cause for
bacteria survival [97] and can account for a high frequency
of mutations responsible for antimicrobial resistance [98]
mediated by triggering enzymatic production, modification
of antibiotic target, or expression of efflux pumps [99–101].
Another mechanism is the appearance of persisters defined
as phenotypically different bacteria exhibiting slower growth
rate [102]. The persisters tend to be located in the biofilm
areas with lower nutrients and oxygen concentrations [87].
For this reason, the phenotypic switch could be regarded
either as bacterial survival strategy in a harsh environment
or a virulence mechanism.The last option is explained by the
decreased activity of the majority of the available antibiotics
against nonreplicative bacteria [103].
For NTM, the boosting of antibiotic resistance promoted
by biofilm assembly seems to be adaptive rather than genetic.
When organized within biofilms, M. avium is transiently
more resistant to antibiotics and antimicrobial agents. Nev-
ertheless, bacteria recovered from biofilms lost resistance in
a short period of time (e.g., 1 day) showing that despite being
a SGM M. avium has a rapid metabolic adaptation rate [3].
This observation also suggests that biofilm induced antibiotic
resistance might be attributed to a structural factor.
Being the scaffold of biofilm, extracellular polymeric
matrix (EPS) is most probably involved in the emergence of
antibiotic resistance. The self-produced EPS is also consid-
ered important for enhancing bacteria virulence. EPS builds
a barrier that can inactivate antibiotic, delaying or preventing
antibiotic penetration within the biofilm and recognition
of their targets [104]. Although EPS composition is not
well known even for the most studied NTM, M. avium
[105], interspecies differences in EPS nature had already
been reported [13]. M. smegmatis EPS is constituted by free
mycolic acid, glycopeptidolipids, andmycolyl-diacylglycerol.
M. abscessus includes mycolyl-diacylglycerol, M. marinum
lipooligosaccharides, and lipopeptides in M. avium subsp.
paratuberculosis [105]. During the biofilm formation and its
establishment, some genes related to the GPL biosynthesis
were upregulated in M. avium and M. smegmatis, showing
that the GPL synthesis and biofilm formation are intimately
connected [106]. For M. smegmatis, it has also been shown
that mycolic acids synthesis is increased in the presence
of antibiotics suggesting a role in the emergence of drug
resistant persisters [107]. In addition to lipids, the presence of
other factors such as GroEL1 [108], protein kinase [109], and
iron [110], or the lack of others, for example, polyphosphate
deficiency, affects biofilm formation, matrix composition,
and structure [111].
The existence ofGPL in the cell wall outermostmembrane
of M. smegmatis and M. avium is associated with the ability
to form biofilms and affects other proprieties such as colonies
morphology, sliding motility, and immune modulation [112].
On the opposite,M. tuberculosis outermost layer, called cap-
sule, is composed of phenolic glycolipids (PGL), phthiocerol
dimycocerosates, and lipooligosaccharides [106, 113].
The cell-surface structures, such as pili, may have an
important role in biofilm formation and surface attachment,
like on some other bacteria [114]. Considering NTM, there
are no studies available that correlate the existence of pili
and surface adherence. Moreover, most of the published
studies on biofilms were conducted on the model organism
M. smegmatis and although NTM are devoid of flagella [115],
it has been shown that the genetic requirements for sliding
motility on agar surfaces and biofilm formation are similar
[116]. A relation between sliding and biofilm assembly has
also been established forM. chelonae andM. fortuitum [117].
6. Methodologies Used to Study Biofilms
Most of the studies in the biofilm field are focused on the
identification of factors involved in the first phase of biofilm
assembly: attachment. However, the last and less understood
phase of biofilm assembly has also been the focus of several
studies [118]. The methodologies followed are diverse and
goal oriented.
The most common method used for following biofilm
assembly in vitro is the microtiter plate test, which allows the
observation of bacterial adherence on abiotic surfaces [119].
Stain techniques with crystal violet allow the visualization
of biofilm and its quantification through spectrophotometry
measurement. The microtiter plate test is the cheapest and
less labour-intensive method [119, 120]. The ring test, Congo
red agar, and resazurin assay are other techniques based
on staining procedures coupled with spectrophotometric
methods used for biofilm study [121–124].
Another technique that has been used is the microfer-
mentor test that generates abundant biomass. This method
have the advantage of allowing the extraction of nucleic
acids and proteins, providing more information on biofilm
assembly [118, 125]. For example, adhesins necessary for
irreversible surface adhesion have been identified by genetic
studies. However, the experimental support for the role
played by these proteins in cell-surface interactions is still
missing [126]. The use of cutting-edge technologies like
next generation sequencing (NGS) and RNA sequencing
to biofilms of different microorganisms is opening new
perspectives [127–129]. The study of gene expression has
become a major interest during the last decade, because it
















Figure 1: NTM persist in a steady state between planktonic (a) and biofilm (b) within healthcare units and on medical devices. Biofilm
assembly is triggered by environmental stress. Bacteria organized in biofilm exhibit a different structure being notorious, increasing the
amount of extracellular matrix (red arrows). Another feature of these bacteria is the increased resistance to chemical sterilization, which
leads to persistence within healthcare units, host colonization, and onset of disease. (Red circles: dead bacteria; green circles: live bacteria;
scale bar 1 𝜇m.)
reveals important data on how bacteria sense and respond to
various environments [127].
Atomic force microscopy (AFM) has also been used in
the field [130]. This method presents a sensitive tool to study
bacterial adhesion to surface [126]. Additionally, AFM allows
the study of bacteria morphology [131] and surfaces with
high resolution. This technique requires minimal sample
preparation and allows the acquisition of 3D images of the
surface ultrastructure in physiological conditions [126]. The
huge potential of this technique could be enhanced by com-
bination with confocal microscopy [132]. Since AFM imaging
has raised several problems [132], other techniques have
been used for this purpose, as scanning electron microscopy
(SEM), transmission electron microscopy (TEM), fluores-
cence microscopy, or confocal laser scanning microscopy
(CLSM) [133–136].
Fluorescence microscopy is a noninvasive method to
assess biofilms, for example, the reactivity of an antibiotic
in a biofilm [137]. Confocal laser scanning microscope is an
optical microscopy technique, useful for the study of more
thick samples [120]. This technique has been also important
to analyse antimicrobials action; however, it has restricted
magnification [137, 138]. Other possible techniques are cryo-
SEM and environmental SEM (ESEM), where samples do
not need to be dehydrated [138]. On cryo-SEM the sample
is frozen with liquid nitrogen during the imaging; however,
micrographs have less resolution compared to SEM or TEM
[138].
The development and standardization ofmethods to eval-
uate minimal inhibitory concentrations (MIC) of antibiotics
against biofilms is a hot topic in biofilm research and clinical
practice. Increased antibiotic resistance by bacteria within
biofilms required the design of different therapeutic schemes
and the determination of MICs is the first step towards
success. An assay to evaluate biofilm susceptibility to biocides
known as MBEC (MBEC Biofilm Technologies Ltd., Calgary,
AB, Canada) system has been developed. A unique 96-well
plate with pegs projecting down from a plastic lid has been
designed to evaluate antibiofilm activity of a battery of drugs
in parallel [139]. Each well can be used to test a different
antibiotic concentration, mimicking the MIC method used
for evaluating antibiotic susceptibility of planktonic bacteria.
The comparison of biofilm and planktonic bacteria suscep-
tibility to antibiotics is one of the major advantages of this
methodology concerning clinical applications [17].
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7. Final Remarks
NTM are emergent pathogens with growing impact on
human health. Their condition of environmental bacterial
enables them to persist in a wide range of conditions. In
addition, NTM once submitted to environmental stress can
assemble biofilms (Figure 1), enhancing their resistance to
antimicrobial agents, persistence within healthcare units, and
the probability to colonize and cause disease in humans.This
scenario is particularly problematic since 80% of infections
are caused by bacteria organized in biofilms which are
refractory to many therapeutic agents currently in use.
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